For the quarter ending 2026-03-31, KPTI made $35,066K in revenue. -$22,392K in net income. Net profit margin of -63.86%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue from contract with customer, license and other revenue | 35,066 | 34,079 | 44,044 | 37,929 |
| Cost of sales | 1,345 | 1,484 | 2,113 | 1,051 |
| Research and development | 33,797 | 27,667 | 30,544 | 32,788 |
| Selling, general and administrative | 26,684 | 22,772 | 26,607 | 28,477 |
| Total operating expenses | 61,826 | 51,923 | 59,264 | 62,316 |
| Loss from operations | -26,760 | -17,844 | -15,220 | -24,387 |
| Interest income | 511 | 607 | 553 | 613 |
| Interest expense | 12,553 | 12,619 | 11,008 | 11,228 |
| (loss) gain on extinguishment of debt | - | -62,365 | 0 | 0 |
| Other income, net | 16,411 | -10,044 | -7,418 | -2,210 |
| Total other income, net | 4,369 | -84,421 | -17,873 | -12,825 |
| Loss before income taxes | -22,391 | -102,265 | -33,093 | -37,212 |
| Income tax provision | 1 | -67 | 34 | 40 |
| Net loss | -22,392 | -102,198 | -33,127 | -37,252 |
| Basic EPS | -1.02 | -5,683.666 | -3.82 | -4.32 |
| Diluted EPS | -1.24 | -5,683.666 | -3.82 | -4.32 |
| Basic Average Shares | 22,014 | 17,981 | 8,669 | 8,620 |
| Diluted Average Shares | 24,715 | 17,981 | 8,669 | 8,620 |
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)